Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus

Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus

We investigated the association of SLE flares with patient-reported outcomes (PRO) and healthcare resource utilisation (HCRU) using real-world data. Rheumatologists from the USA, France, Germany, Spain, Italy provided demographic, clinical, and HCRU data for patients with SLE, who provided PRO data....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2022-11
Hauptverfasser: Costenbader, Karen H, Hoskin, Ben, Atkinson, Christian, Bell, David, Pike, James, Lofland, Jennifer H, Berry, Pamela, Karyekar, Chetan S, Touma, Zahi
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Clinical and experimental rheumatology
container_volume
creator Costenbader, Karen H
Hoskin, Ben
Atkinson, Christian
Bell, David
Pike, James
Lofland, Jennifer H
Berry, Pamela
Karyekar, Chetan S
Touma, Zahi
description We investigated the association of SLE flares with patient-reported outcomes (PRO) and healthcare resource utilisation (HCRU) using real-world data. Rheumatologists from the USA, France, Germany, Spain, Italy provided demographic, clinical, and HCRU data for patients with SLE, who provided PRO data. "Flaring" was defined as ≥1 rheumatologist-reported flare in the past 12 months. Demographic/clinical data were analysed descriptively, and findings compared statistically by flaring status. Logistic regression estimated a propensity score for flaring based on ethnicity, disease duration, and severity at diagnosis. Propensity score-matched flaring and non-flaring patients were compared for their HCRU, PROs, income loss and treatment satisfaction. Physicians (n=263) provided data for 1,278 patients (408 flaring/870 non-flaring); 729 patients (241 flaring/488 non-flaring) provided matched patient data. Patients had a mean 2.1 flares in the previous 12 months. Propensity score matched analyses indicated worse outcomes and greater HCRU in the past 12 months in flaring than non-flaring patients: EuroQoL 5D-3L Utility Index: 0.72 vs. 0.83; Functional Assessment of Chronic Illness Therapy-Fatigue scale: 30.06 vs. 36.48; Work Productivity and Activity Impairment Index: absenteeism 5.87% vs. 2.53% / presenteeism 33.44% vs. 19.16% / overall work impairment 35.98% vs. 20.66% / total activity impairment 42.47% vs. 30.23%; healthcare consultations (8.10 vs. 6.41), hospitalisations (24.26 vs. 7.63), emergency department visits (20.83 vs. 4.19), tests (46.59 vs. 38.90); current medications (2.76 vs. 2.19) (all p
doi_str_mv 10.55563/clinexprheumatol/k9yyeq
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_55563_clinexprheumatol_k9yyeq</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34905485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c227t-cd4b01bdf2132ea6ba05b11f0e4081e8cf1b8eeff4df3e078758547e5873be0f3</originalsourceid><addsrcrecordid>eNpd0M1KxDAUhuEgijOO3oLkBuokTdOmSxH_YEAQhdmVND2x0bap-UG78N6tjrpwdVbP4eNFCFNyxjnP2Vp1ZoD30bUQexlst34ppwle99CS8pIlpBTbfbQkrEwTwfPtAh15_0xImvO8OEQLlpWEZ4Iv0cc9yC55s65rsOlHqQK2GutOOjM8YTvgUQYDQ0gcjNYFaLCNQdkePJZDg9tZh1ZJB9iBt9EpwDGYzviZzdoM2E8-QG8U7uIYPQY3hRa-Rvvoj9GBlp2Hk5-7Qo9Xlw8XN8nm7vr24nyTqDQtQqKarCa0bnRKWQoyryXhNaWaQEYEBaE0rQWA1lmjGZBCFFzwrAAuClYD0WyFxO6vctZ7B7oanemlmypKqu-i1f-i1a7oTE93dIx1D80f_E3IPgFK-3-d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus</title><source>Alma/SFX Local Collection</source><creator>Costenbader, Karen H ; Hoskin, Ben ; Atkinson, Christian ; Bell, David ; Pike, James ; Lofland, Jennifer H ; Berry, Pamela ; Karyekar, Chetan S ; Touma, Zahi</creator><creatorcontrib>Costenbader, Karen H ; Hoskin, Ben ; Atkinson, Christian ; Bell, David ; Pike, James ; Lofland, Jennifer H ; Berry, Pamela ; Karyekar, Chetan S ; Touma, Zahi</creatorcontrib><description>We investigated the association of SLE flares with patient-reported outcomes (PRO) and healthcare resource utilisation (HCRU) using real-world data. Rheumatologists from the USA, France, Germany, Spain, Italy provided demographic, clinical, and HCRU data for patients with SLE, who provided PRO data. "Flaring" was defined as ≥1 rheumatologist-reported flare in the past 12 months. Demographic/clinical data were analysed descriptively, and findings compared statistically by flaring status. Logistic regression estimated a propensity score for flaring based on ethnicity, disease duration, and severity at diagnosis. Propensity score-matched flaring and non-flaring patients were compared for their HCRU, PROs, income loss and treatment satisfaction. Physicians (n=263) provided data for 1,278 patients (408 flaring/870 non-flaring); 729 patients (241 flaring/488 non-flaring) provided matched patient data. Patients had a mean 2.1 flares in the previous 12 months. Propensity score matched analyses indicated worse outcomes and greater HCRU in the past 12 months in flaring than non-flaring patients: EuroQoL 5D-3L Utility Index: 0.72 vs. 0.83; Functional Assessment of Chronic Illness Therapy-Fatigue scale: 30.06 vs. 36.48; Work Productivity and Activity Impairment Index: absenteeism 5.87% vs. 2.53% / presenteeism 33.44% vs. 19.16% / overall work impairment 35.98% vs. 20.66% / total activity impairment 42.47% vs. 30.23%; healthcare consultations (8.10 vs. 6.41), hospitalisations (24.26 vs. 7.63), emergency department visits (20.83 vs. 4.19), tests (46.59 vs. 38.90); current medications (2.76 vs. 2.19) (all p&lt;0.001 except absenteeism, p=0.004). Similar flaring SLE patients had worse PROs and higher HCRU than non-flaring patients, underscoring the need for more effective strategies and treatments to alleviate or prevent flaring.</description><identifier>ISSN: 0392-856X</identifier><identifier>ISSN: 1593-098X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>DOI: 10.55563/clinexprheumatol/k9yyeq</identifier><identifier>PMID: 34905485</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2022-11</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34905485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costenbader, Karen H</creatorcontrib><creatorcontrib>Hoskin, Ben</creatorcontrib><creatorcontrib>Atkinson, Christian</creatorcontrib><creatorcontrib>Bell, David</creatorcontrib><creatorcontrib>Pike, James</creatorcontrib><creatorcontrib>Lofland, Jennifer H</creatorcontrib><creatorcontrib>Berry, Pamela</creatorcontrib><creatorcontrib>Karyekar, Chetan S</creatorcontrib><creatorcontrib>Touma, Zahi</creatorcontrib><title>Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>We investigated the association of SLE flares with patient-reported outcomes (PRO) and healthcare resource utilisation (HCRU) using real-world data. Rheumatologists from the USA, France, Germany, Spain, Italy provided demographic, clinical, and HCRU data for patients with SLE, who provided PRO data. "Flaring" was defined as ≥1 rheumatologist-reported flare in the past 12 months. Demographic/clinical data were analysed descriptively, and findings compared statistically by flaring status. Logistic regression estimated a propensity score for flaring based on ethnicity, disease duration, and severity at diagnosis. Propensity score-matched flaring and non-flaring patients were compared for their HCRU, PROs, income loss and treatment satisfaction. Physicians (n=263) provided data for 1,278 patients (408 flaring/870 non-flaring); 729 patients (241 flaring/488 non-flaring) provided matched patient data. Patients had a mean 2.1 flares in the previous 12 months. Propensity score matched analyses indicated worse outcomes and greater HCRU in the past 12 months in flaring than non-flaring patients: EuroQoL 5D-3L Utility Index: 0.72 vs. 0.83; Functional Assessment of Chronic Illness Therapy-Fatigue scale: 30.06 vs. 36.48; Work Productivity and Activity Impairment Index: absenteeism 5.87% vs. 2.53% / presenteeism 33.44% vs. 19.16% / overall work impairment 35.98% vs. 20.66% / total activity impairment 42.47% vs. 30.23%; healthcare consultations (8.10 vs. 6.41), hospitalisations (24.26 vs. 7.63), emergency department visits (20.83 vs. 4.19), tests (46.59 vs. 38.90); current medications (2.76 vs. 2.19) (all p&lt;0.001 except absenteeism, p=0.004). Similar flaring SLE patients had worse PROs and higher HCRU than non-flaring patients, underscoring the need for more effective strategies and treatments to alleviate or prevent flaring.</description><issn>0392-856X</issn><issn>1593-098X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpd0M1KxDAUhuEgijOO3oLkBuokTdOmSxH_YEAQhdmVND2x0bap-UG78N6tjrpwdVbP4eNFCFNyxjnP2Vp1ZoD30bUQexlst34ppwle99CS8pIlpBTbfbQkrEwTwfPtAh15_0xImvO8OEQLlpWEZ4Iv0cc9yC55s65rsOlHqQK2GutOOjM8YTvgUQYDQ0gcjNYFaLCNQdkePJZDg9tZh1ZJB9iBt9EpwDGYzviZzdoM2E8-QG8U7uIYPQY3hRa-Rvvoj9GBlp2Hk5-7Qo9Xlw8XN8nm7vr24nyTqDQtQqKarCa0bnRKWQoyryXhNaWaQEYEBaE0rQWA1lmjGZBCFFzwrAAuClYD0WyFxO6vctZ7B7oanemlmypKqu-i1f-i1a7oTE93dIx1D80f_E3IPgFK-3-d</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Costenbader, Karen H</creator><creator>Hoskin, Ben</creator><creator>Atkinson, Christian</creator><creator>Bell, David</creator><creator>Pike, James</creator><creator>Lofland, Jennifer H</creator><creator>Berry, Pamela</creator><creator>Karyekar, Chetan S</creator><creator>Touma, Zahi</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221101</creationdate><title>Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus</title><author>Costenbader, Karen H ; Hoskin, Ben ; Atkinson, Christian ; Bell, David ; Pike, James ; Lofland, Jennifer H ; Berry, Pamela ; Karyekar, Chetan S ; Touma, Zahi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c227t-cd4b01bdf2132ea6ba05b11f0e4081e8cf1b8eeff4df3e078758547e5873be0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costenbader, Karen H</creatorcontrib><creatorcontrib>Hoskin, Ben</creatorcontrib><creatorcontrib>Atkinson, Christian</creatorcontrib><creatorcontrib>Bell, David</creatorcontrib><creatorcontrib>Pike, James</creatorcontrib><creatorcontrib>Lofland, Jennifer H</creatorcontrib><creatorcontrib>Berry, Pamela</creatorcontrib><creatorcontrib>Karyekar, Chetan S</creatorcontrib><creatorcontrib>Touma, Zahi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costenbader, Karen H</au><au>Hoskin, Ben</au><au>Atkinson, Christian</au><au>Bell, David</au><au>Pike, James</au><au>Lofland, Jennifer H</au><au>Berry, Pamela</au><au>Karyekar, Chetan S</au><au>Touma, Zahi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2022-11-01</date><risdate>2022</risdate><issn>0392-856X</issn><issn>1593-098X</issn><eissn>1593-098X</eissn><abstract>We investigated the association of SLE flares with patient-reported outcomes (PRO) and healthcare resource utilisation (HCRU) using real-world data. Rheumatologists from the USA, France, Germany, Spain, Italy provided demographic, clinical, and HCRU data for patients with SLE, who provided PRO data. "Flaring" was defined as ≥1 rheumatologist-reported flare in the past 12 months. Demographic/clinical data were analysed descriptively, and findings compared statistically by flaring status. Logistic regression estimated a propensity score for flaring based on ethnicity, disease duration, and severity at diagnosis. Propensity score-matched flaring and non-flaring patients were compared for their HCRU, PROs, income loss and treatment satisfaction. Physicians (n=263) provided data for 1,278 patients (408 flaring/870 non-flaring); 729 patients (241 flaring/488 non-flaring) provided matched patient data. Patients had a mean 2.1 flares in the previous 12 months. Propensity score matched analyses indicated worse outcomes and greater HCRU in the past 12 months in flaring than non-flaring patients: EuroQoL 5D-3L Utility Index: 0.72 vs. 0.83; Functional Assessment of Chronic Illness Therapy-Fatigue scale: 30.06 vs. 36.48; Work Productivity and Activity Impairment Index: absenteeism 5.87% vs. 2.53% / presenteeism 33.44% vs. 19.16% / overall work impairment 35.98% vs. 20.66% / total activity impairment 42.47% vs. 30.23%; healthcare consultations (8.10 vs. 6.41), hospitalisations (24.26 vs. 7.63), emergency department visits (20.83 vs. 4.19), tests (46.59 vs. 38.90); current medications (2.76 vs. 2.19) (all p&lt;0.001 except absenteeism, p=0.004). Similar flaring SLE patients had worse PROs and higher HCRU than non-flaring patients, underscoring the need for more effective strategies and treatments to alleviate or prevent flaring.</abstract><cop>Italy</cop><pmid>34905485</pmid><doi>10.55563/clinexprheumatol/k9yyeq</doi></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2022-11
issn 0392-856X
1593-098X
1593-098X
language eng
recordid cdi_crossref_primary_10_55563_clinexprheumatol_k9yyeq
source Alma/SFX Local Collection
title Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T03%3A51%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20impact%20of%20flaring%20on%20patient-reported%20outcomes%20and%20healthcare%20resource%20utilisation%20in%20systemic%20lupus%20erythematosus&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Costenbader,%20Karen%20H&rft.date=2022-11-01&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/10.55563/clinexprheumatol/k9yyeq&rft_dat=%3Cpubmed_cross%3E34905485%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34905485&rfr_iscdi=true